The company’s success has been largely built on its HIV treatment portfolio, including the blockbuster drug Biktarvy. Gilead has demonstrated strong operational execution, effectively ...

Citi remains “very bullish” on Gilead’s HIV franchise, based on a “meaningful” new product cycle for long-acting orals that it thinks is overlooked by investors. It now models Biktarvy ...

On Wednesday, Gilead Sciences, Inc ... ALLIANCE is an ongoing Phase 3 study evaluating Biktarvy versus dolutegravir 50 mg (DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg ...